Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases

Genes Chromosomes and Cancer

Volumn 54, Issue 6, 2015, Pages 369-382

  Marsaud, Alexandre ^a,b   Dadone, Bérengère ^a,b   Ambrosetti, Damien ^a,b   Baudoin, Christian ^a   Chamorey, Emmanuel ^c   Rouleau, Etienne ^d   Lefol, Cédrick ^d   Roussel, Jean François ^e   Fabas, Thibault ^b   Cristofari, Gaël ^a   Carpentier, Xavier ^b   Michiels, Jean François ^b   Amiel, Jean ^b   Pedeutour, Florence ^a,b  

^a UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d INSTITUT CURIE   (France)

^e CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; SCATTER FACTOR RECEPTOR; SUNITINIB; VIMENTIN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHROMOSOME 12; CHROMOSOME 14; CHROMOSOME 17; CHROMOSOME 7; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PAPILLARY RENAL CELL CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; ROBERTSONIAN CHROMOSOME TRANSLOCATION; Y CHROMOSOME; CLASSIFICATION; GENETIC HETEROGENEITY; GENETICS; KIDNEY TUMOR; METABOLISM; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENETIC HETEROGENEITY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84928017380     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22248     Document Type: Article

References (47)

1. Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z, Molinie V, Allory Y, Orear C, Couvé S, Gad S, Patard JJ, Escudier B. 2014. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res 20:3411-3421.
2. Antonelli A, Tardanico R, Balzarini P, Arrighi N, Perucchini L, Zanotelli T, Cozzoli A, Zani D, Cunico SC, Simeone C. 2010. Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet Cytogenet 199:128-133.
3. Argani P, Ladanyi M. 2004. Renal carcinomas associated with Xp11.2 translocations / TFE3 gene fusions. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC. pp. 37-38.
4. Balint I, Szponar A, Jauch A, Kovacs G. 2009. Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype. J Clin Pathol 62:892-895.
5. Bellmunt J, Dutcher J. 2013. Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol 24:1730-1740.
6. Bentz M, Bergerheim US, Li C, Joos S, Werner CA, Baudis M, Gnarra J, Merino MJ, Zbar B, Linehan WM, Lichter P. 1996. Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenet Cell Genet 75:17-21.
7. Bertolotto C, Lesueur F, Bressac de Paillerets B. 2012. MITF: a genetic key to melanoma and renal cell carcinoma?. Med Sci 28:258-261.
8. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925.
9. Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S. 2012. BRAF mutations in metanephric adenoma of the kidney. Eur Urol 62:917-922.
10. Dadone B, Ambrosetti D, Carpentier X, Duranton-Tanneur V, Burel-Vandenbos F, Amiel J, Pedeutour F. 2013. A renal metanephric adenoma showing both a 2p16-24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?. Cancer Genet 206: 347-352.
11. Delahunt B, Eble JN. 1997. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537-544.
12. Delahunt B, Eble JN. 2004. Papillary renal cell carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC. 2004. pp. 27-29.
13. Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S. 2015. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet 47:13-21.
14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group. 2007a. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134.
15. Escudier B, Pluzanska A, Koralewski P, Ravaud A Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, AVOREN Trial investigators. 2007b. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111.
16. Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P, Kataja V, ESMO Guidelines Working Group. 2012. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii65-vii71.
17. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
18. Fletcher CDM, Chibon F, Mertens F. 2013. Undifferentiated/unclassified sarcomas. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. Lyon: IARC. pp. 236-238.
19. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ. 2015. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43(Database issue):D805-11.
20. Fuhrman SA, Lasky LC, Limas C. 1982. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663.
21. Gobbo S, Eble JN, Maclennan GT, Grignon DJ, Shah RB, Zhang S, Martignoni G, Brunelli M, Cheng L. 2008. Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am J Surg Pathol 32:1780-1786.
22. Grépin R, Ambrosetti D, Marsaud A, Gastaud L, Amiel J, Pedeutour F, Pagès G. 2014. The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma. PloS One 9:e89449.
23. Gunawan B, von Heydebreck A, Fritsch T, Huber W, Ringert RH, Jakse G, Füzesi L. 2003. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 63:6200-6205.
24. Hagenkord JM, Gatalica Z, Jonasch E, Monzon FA. 2011. Clinical genomics of renal epithelial tumors. Cancer Genet 204:285-297.
25. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H. 1998. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 153:1467-1473.
26. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS. 2009. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 15:1162-1169.
27. Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. 2011. Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol 185:30-35.
28. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PFA, Sinescu IC, European Association of Urology Guideline Group 2010. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398-406.
29. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, Walther MM, Choyke P, Linehan WM, Zbar B. 1999. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155:517-526.
30. Malouf GG, Monzon FA, Couturier J, Molinie V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM. 2013. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 19:4673-4684.
31. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. 2010. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinforma Oxf Engl 26:2069-2070.
32. Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ. 2012. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 30:335-340.
33. Moore LE, Jaeger E, Nickerson ML, Brennan P, De Vries S, Roy R, Toro J, Li H, Karami S, Lenz P, Zaridze D, Janout V, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Linehan WM, Merino M, Simko J, Pfeiffer R, Boffetta P, Hewitt S, Rothman N, Chow WH, Waldman FM. 2012. Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation. Oncogenesis 1:e14.
34. Paglino C, Imarisio I, Ganini C, Morbini P, Vercelli A, Bregant C, Porta C. 2012. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. Future Oncol 8:1605-1612.
35. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, Sagalowsky AI, Summerour PB, Kabbani W, Wong SW, Grishin N, Laurent M, Xie XJ, Haudenschild CD, Ross MT, Bentley DR, Kapur P, Brugarolas J. 2012. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44: 751-759.
36. Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. 2005. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25:5675-5686.
37. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. 2011. Integrative genomics viewer. Nat Biotechnol 29:24-26.
38. Sanders ME, Mick R, Tomaszewski JE, Barr FG. 2002. Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol 161:997-1005.
39. Scagliotti GV, Novello S, von Pawel J. 2013. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 39:793-801.
40. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V, Bergeron C, Michon J, Delattre O. 2010. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 28:3122-3130.
41. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B. 1999. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350.
42. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P, ISUP Renal Tumor Panel. 2013. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 37:1469-1489.
43. Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G. 2009. Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer 124: 2071-2076.
44. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. 2012. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62:1013-1019.
45. Toro JR, Nickerson ML, Wei MH, Warren MB Glenn GM, Turner ML, Stewart L, Duray P, Tourre O, Sharma N, Choyke P, Stratton P, Merino M, Walther MM, Linehan WM, Schmidt LS, Zbar B. 2003. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73:95-106.
46. Truong LD, Shen SS. 2011. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med 135:92-109.
47. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. 2005. A molecular classification of papillary renal cell carcinoma. Cancer Res 65:5628-5637.